Pharmacodynamics, pharmacokinetics and safety of GSK2190915, a novel oral anti‐inflammatory 5‐lipoxygenase‐activating protein inhibitor

AIM: To assess the pharmacokinetics, pharmacodynamics, safety and tolerability of the 5‐lipoxygenase‐activating protein inhibitor, GSK2190915, after oral dosing in two independent phase I studies, one in Western European and one in Japanese subjects, utilizing different formulations. METHOD: Western...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Bain, Gretchen, King, Christopher D., Schaab, Kevin, Rewolinski, Melissa, Norris, Virginia, Ambery, Claire, Bentley, Jane, Yamada, Masanori, Santini, Angelina M., van de Wetering de Rooij, Jeroen, Stock, Nicholas, Zunic, Jasmine, Hutchinson, John H., Evans, Jilly F.
Formato: Artigo
Idioma:Inglês
Publicado em: Blackwell Publishing Ltd 2013
Assuntos:
Pharmacodynamics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3575944/
https://ncbi.nlm.nih.gov/pubmed/22803688
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2012.04386.x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados